Patients responding to one form of hormonal treatment had a greater likelihood of responding to subsequent hormonal manipulations. Additive hormonal therapy may provide effective palliation in males with advanced breast...
[6]Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers (Basel). 2021 Jun 11;13(12):2927. [7] Brufsky AM, Mayer M, Rugo HS...
[3] Galanti D, Inno A, La Vecchia M, et al. Current treatment options for HER2-positive breast cancer patients with brain metastases. Crit Rev Oncol Hematol. 2021 May;161:103329. [4] Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Br...
[3] Huo X, Shen G, Wang T, et al. Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis. Front Oncol. 2023;13:1003565. [4] Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer ...
HER2-directed therapy: current treatment options for HER2-positive breast cancer Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imagin... S Ahmed,A Sami,J Xiang - 《Breast Cancer》 被引量: 74...
2. Saini KS, et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast. 2011;20(Suppl 3):S20–7. 3. Capelan M, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82. ...
[3] GianniL, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2 positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superioritytrial with a parallel HER2-negative cohort[J]. Lancet Oncol,2014,15(6):640-647. ...
S. Rugo, "Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options," ... H Jiang,HS Rugo - 《Therapeutic Advances in Medical Oncology》 被引量: 21发表: 2015年 Treatment strategies for hormone receptor-positive,...
Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer. Sara A. Hurvitz, MD The year 2020 saw a myriad of promising studies that resulted in several FDA-approved options for patients wit...
[1]Li Y, Tong Z, Wu X, et al. Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study. Int J Cancer. 2023 Aug 6. ...